MedPath

Study to estimate the efficacy of heat-killed Lactobacillus (K15) to privent infection in infant after discharge from NICU or GCU; double-blind, randomized controlled trial

Not Applicable
Conditions
infants who were born within gestational age of 35 weeks or less and were treated in and discharged from NICU or GC
Registration Number
JPRN-UMIN000036440
Lead Sponsor
Graduate School of Medicine, Chiba University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
70
Inclusion Criteria

Not provided

Exclusion Criteria

1) infants who have allergy to Lactobacillus preparation or products derived from soy 2) infants who have congenital heart defect, severe respiratory disorder, chromosomal abnormality, or primary immunodeficiency 3) infants who are considered unsuitable to participate in this study by attending physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
duration of fever episodes
Secondary Outcome Measures
NameTimeMethod
1. frequency of respiratory tract infection 2. severity of respiratory tract infection 3. frequency of Respiratory syncytial virus (RSV) infection diagnosed by physician 4. Severity of respiratory disorder 5. Serum IgG, IgA, IgM before and after treatment 6. side effects related to K15 administration
© Copyright 2025. All Rights Reserved by MedPath